Suscribirse

Multicenter, multinational, prospective cohort study of the impact of chlorhexidine impregnated versus plain central lines on central line-associated bloodstream infections - 11/07/25

Doi : 10.1016/j.ajic.2025.03.002 
Victor Daniel Rosenthal, MD, PhD a, b, , Ruijie Yin, PhD a, Zhilin Jin, PhD a, Mat Nor Mohd Basri, MD c, Lai Yin Hoong, MD c, Fatimah Mohamad, MD c, Amani El-Kholy, MD d, Victor Bayani, RN d, Rana Hatem, MD d, Sheila Nainan Myatra, MD e, Linda Castro Páez, RN f, Mohit Kharbanda, MD g, Bikas Nag, RN g, Ertugrul Guclu, MD h, Esra Olmez Gazioglu, MD h, Sunita Gupta, MD i, Nellie Tumu, RN j
a Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA 
b INICC Foundation, International Nosocomial Infection Control Consortium, Miami, FL, USA 
c International Islamic University Malaysia Department of Anesthesia and Critical Care, Kuantan, Malaysia 
d Cairo University Dar Alfouad Hospital, 6th of October City, Egypt 
e Tata Memorial Hospital Homi Bhabha National Institute, Mumbai, India 
f Department of Infection Control, Clinica Iberoamerica de Clinicas Colsanitas, Barranquilla, Colombia 
g Department of Critical Care, Desun Hospital, Kolkata, India 
h Department of Microbiology, Sakarya University Training and Research Hospital, Sakarya, Turkey 
i Department of Microbiology, Santokba Durlabhji Memorial Hospital, Jaipur, India 
j Department of Infection Control, Port Moresby General Hospital, Port Moresby, Papua New Guinea 

Address correspondence to Victor Daniel Rosenthal, MD, PhD, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 N.W. 14th Street, Floor 9, Office 912, Miami, FL 33136.Department of Public Health Sciences, University of Miami Miller School of Medicine1120 N.W. 14th Street, Floor 9, Office 912MiamiFL33136

Resumen

Background

We compared the efficacy of chlorhexidine-impregnated central lines (CLs) with plain CLs in preventing central line-associated bloodstream infections (CLABSIs) in critically ill patients.

Methods

The study was conducted from April 2023 to August 2024 in 8 hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. Data were collected prospectively using the INICC Surveillance Online System. Cases and controls were recruited simultaneously. Data were analyzed using t tests, χ² tests, and Fisher exact tests when indicated. Relative risks (RR) and their corresponding 95% confidence intervals (CI) were calculated.

Results

A total of 6,672 patients were included. Patients with impregnated CLs had 4,721 CL-days, while those with plain CLs had 18,822 CL-days. The CLABSI rate in patients with impregnated CLs was 1.48 per 1,000 CL-days, compared to 4.78 per 1,000 CL-days in those with plain CLs (RR=0.31, 95%CI=0.14-0.67, P=.003). A subgroup analysis excluding patients with hemodialysis but using central venous catheters (CVCs) showed 1.72 CLABSIs per 1,000 CL-days in patients with impregnated CVCs compared to 5.84 per 1,000 CL-days in those with plain CVCs (RR=0.29, 95%CI=0.12-0.68, P=.004).

Conclusions

This study highlights the significant benefits of impregnated CLs over plain CLs in reducing CLABSI rates, achieving a 69% decrease in incidence.

El texto completo de este artículo está disponible en PDF.

Highlights

This study evaluates the impact of CHG-impregnated central lines on the CLABSI rate.
An intervention was conducted in 12 ICUs across eight hospitals in 6 countries.
A total of 6,672 patients were studied.
The CLABSI rate was lower in patients with impregnated catheters than those with plain ones.

El texto completo de este artículo está disponible en PDF.

Key Words : Impregnated catheters, Chlorhexidine-impregnated catheters, Middle-income countries, Developing countries, Limited resources countries, Network


Esquema


 Funding/support: The funding for the design, development, maintenance, technical support, data validation, and report generation of ISOS and the activities conducted at INICC headquarters was provided by the corresponding author, Victor D. Rosenthal, and the INICC Foundation. Teleflex provided financial support for the manuscript's editing but did not influence or contribute to the data analysis or the editing of the manuscript.
 Conflicts of interest: Rosenthal, V.D. is an occasional speaker for Teleflex but does not have employment, stock ownership, honoraria, paid expert testimony, or patent applications/registrations associated with Teleflex. The remaining authors declare that they have no financial or personal relationships with other individuals or organizations that could inappropriately influence their work, and they have no potential competing interests, including but not limited to roles as speakers, employment, stock ownership, honoraria, paid expert testimony, or patent applications/registrations.


© 2025  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 53 - N° 8

P. 862-868 - août 2025 Regresar al número
Artículo precedente Artículo precedente
  • Health care-associated infections and antimicrobial use: The third point prevalence survey on 42 acute care hospitals in Piedmont, Italy, 2022
  • Antonino Russotto, Claudia Gastaldo, Stefania Di Giacomo, Stefano Bazzolo, Dario Gamba, Carla Maria Zotti, Costanza Vicentini, on behalf of the “UPRI” working group
| Artículo siguiente Artículo siguiente
  • Implementation of a secure electronic form for bloodborne pathogen exposure reporting associated with increased reports among healthcare workers: A quasi-experimental study
  • Erin Bammann, Himgauri Nikrad, Deborah Aragon, Heather Young

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.